Careers  |  Sign In  |  Register

Latest in Oncology

In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that suggests progression-free survival (PFS) is increased with the use of these targeted therapies. Learn more...
In this interview, Shirish M. Gadgeel, MD, MBBS, medical oncologist at Michigan Medicine, University of Michigan, provides insights into multikinase tyrosine kinase inhibitor (TKI) treatments and their varied observed efficacy in patients with different tumor types. In particular, he observes that...
A study completed by researchers in China, of patients with renal cell carcinoma (RCC), attempted to both validate previous conclusions and look at the influencing factors of perioperative renal function change and its relationship to patient prognosis after nephrectomy and thrombectomy. The completed...